Pegylated liposomal doxorubicin (PLD) in heavily pretreated epithelial ovarian cancer patients

被引：0
|
作者：
Gorumlu, Gurbuz [1 ]
Kucukzeybek, Yuksel [1 ]
Karabulut, Bulent [1 ]
Terek, Mustafa C. [1 ]
Uslu, Ruchan [1 ]
Sanli, Ulus A. [1 ]
Akman, Levent [1 ]
Ozsaran, Aydin [1 ]
Dikmen, Yilmaz [1 ]
Goker, Erdem [1 ]
机构：
[1] Ege Univ, Izmir, Turkey
来源：
ANNALS OF ONCOLOGY | 2006年 / 17卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：172 / 172
页数：1
相关论文
共 50 条
  • [21] Pembrolizumab plus pegylated liposomal Doxorubicin for Patients with Ovarian Cancer
    Lorenz, Judith
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2021, 81 (01) : 19 - 20
  • [22] Trabectedin in combination with pegylated liposomal doxorubicin for patients with ovarian cancer
    Tavella, K.
    Villanucci, A.
    Vannini, L.
    Montelatici, S.
    Lavacchi, D.
    Boni, L.
    Tomcikova, D.
    Amunni, G.
    Mazzei, T.
    ANNALS OF ONCOLOGY, 2016, 27
  • [23] Pegylated liposomal doxorubicin in ovarian cancer patients with renal compromise
    Basu, C. K.
    Mukhopadhyay, A.
    Pandey, R.
    Dey, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [24] Clinical and pharmacokinetic phase II study of pegylated liposomal doxorubicin and vinorelbine in heavily pretreated recurrent ovarian carcinoma
    Katsaros, D
    Oletti, MV
    de la Longrais, IAR
    Ferrero, A
    Celano, A
    Fracchioli, S
    Donadio, M
    Passera, R
    Cattel, L
    Bumma, C
    ANNALS OF ONCOLOGY, 2005, 16 (02) : 300 - 306
  • [25] CA-125 Response Patterns in Patients With Recurrent Ovarian Cancer Treated With Pegylated Liposomal Doxorubicin (PLD)
    Oaknin, Ana
    Barretina, Pilar
    Perez, Xavier
    Jimenez, Laura
    Velasco, Montserrat
    Alsina, Maria
    Brunet, Joan
    Ramon Germa, Josep
    Beltran, Miguel
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2010, 20 (01) : 87 - 91
  • [26] Efficacy of pegylated liposomal doxorubicin (PLD) plus carboplatin in patients with intermediate sensitive relapsing advanced ovarian cancer
    Stuart, G.
    Oza, A.
    Provencher, D.
    Bentley, J.
    Plante, M.
    Lotocki, R.
    Power, P.
    Miller, D.
    Ghatage, P.
    Pouliot, J.
    EJC SUPPLEMENTS, 2005, 3 (02): : 272 - 272
  • [27] Pegylated liposomal doxorubicin HCL (PLD; Caelyx/Doxil®):: Experience with long-term maintenance in responding patients with recurrent epithelial ovarian cancer
    Andreopoulou, E.
    Gaiotti, D.
    Kim, E.
    Downey, A.
    Mirchandani, D.
    Hamilton, A.
    Jacobs, Allan
    Curtin, John
    Muggia, F.
    ANNALS OF ONCOLOGY, 2007, 18 (04) : 716 - 721
  • [28] Safety and efficacy of metronomic non-pegylated liposomal encapsulated doxorubicin in heavily pretreated advanced breast cancer patients
    Manso, L.
    Valdiviezo, N.
    Sepulveda, J.
    Ciruelos, E.
    Mendiola, C.
    Ghanem, I.
    Vega, E.
    Manneh, R.
    Dorta, M.
    Cortes-Funes, H.
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2013, 15 (06): : 467 - 471
  • [29] Phase I safety study of farletuzumab, carboplatin, and pegylated liposomal doxorubicin (PLD) in patients with platinum-sensitive epithelial ovarian cancer (EOC)
    Kim, Kenneth H.
    Jelovac, Danijela
    Armstrong, Deborah Kay
    Weil, Susan
    Phillips, Martin
    Schwartz, Benjamin M.
    Estes, Jacob Michael
    Alvarez, Ronald David
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [30] Safety and efficacy of metronomic non-pegylated liposomal encapsulated doxorubicin in heavily pretreated advanced breast cancer patients
    L. Manso
    N. Valdiviezo
    J. Sepúlveda
    E. Ciruelos
    C. Mendiola
    I. Ghanem
    E. Vega
    R. Manneh
    M. Dorta
    H. Cortés-Funes
    Clinical and Translational Oncology, 2013, 15 : 467 - 471
12345